Last reviewed 2026-04-20 · How we verify

Toltrazuril Sulfone (PONAZURIL)

PONAZURIL, a marketed drug by an unspecified company, effectively combats coccidian parasites through its mechanism of inhibiting their growth and replication. A key strength of PONAZURIL is its protected market position, with the key composition patent expiring in 2028. The primary risk to PONAZURIL's market position is the potential increase in competition following the patent expiry in 2028.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• ADVANCE-D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy (PHASE4)
• X-Change HF - Exchange of the Existing Pacemaker/ICD in Bradycardia Patients Suffering From Heart Failure (PHASE4)
• CORE: Study to Evaluate the Conducted AF-Response-Algorithm in Patients Suffering From Heart Failure and Atrial Fibrillation (PHASE4)
• DATAS: The Dual Chamber & Atrial Tachyarrhythmias Adverse Events Study (NA)
• MAVRIC VR ICD Registry
• AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study (PHASE3)
• RIGHT: Rhythm ID Going Head-to-Head Trial (PHASE4)
• InSync III Marquis Model 7279 Cardioverter Defibrillator Cardiac Resynchronization System (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.